Natera Wins Preliminary Injunction In Patent Infringement Lawsuit Against NeoGenomics' RaDaR Test
Portfolio Pulse from Benzinga Newsdesk
Natera has secured a preliminary injunction in its patent infringement lawsuit against NeoGenomics, which prevents NeoGenomics from making, using, selling, or promoting its RaDaR MRD assay in the U.S., with some exceptions.
December 28, 2023 | 7:02 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NeoGenomics faces a negative impact from the preliminary injunction, which could lead to a short-term decline in its stock price due to the restriction on its RaDaR MRD assay.
The injunction against NeoGenomics restricts one of its products, which could negatively affect its revenue and market position. This legal hurdle may concern investors and could result in a short-term decrease in NeoGenomics' stock price as the market digests the news.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Natera's win in the preliminary injunction may positively influence investor sentiment, potentially leading to a short-term uptick in its stock price.
The preliminary injunction is a significant legal win for Natera, indicating a strong position in the ongoing patent infringement case. This could lead to increased investor confidence and a potential rise in stock price as the market reacts to the positive legal development.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80